Arcellx Investor Relations Material
Latest events
Status Update
Arcellx
Q1 2025
8 May, 2025
Q4 2024
27 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Arcellx Inc
Access all reports
Arcellx, Inc. is a clinical-stage biotechnology company focused on developing innovative cell therapies for the treatment of cancer and other severe diseases. The company's approach centers around engineering immunotherapies, particularly those based on CAR-T cell technology, to target specific cancers. Arcellx is headquartered in Redwood City, California, and its shares are listed on NASDAQ.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
ACLX
Country
🇺🇸 United States